No Data
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $437,325, According to a Recent SEC Filing
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Delivers Shareholders Stellar 23% CAGR Over 5 Years, Surging 4.7% in the Last Week Alone
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Jefferies Initiates Kiniksa Pharmaceuticals at Buy With $40 Price Target
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
Jefferies analyst Roger Song initiates coverage on $Kiniksa Pharmaceuticals International(KNSA.US)$ with a buy rating, and sets the target price at $40.According to TipRanks data, the analyst has a
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39
J.P. Morgan analyst Anupam Rama maintains $Kiniksa Pharmaceuticals International(KNSA.US)$ with a buy rating, and adjusts the target price from $38 to $39.According to TipRanks data, the analyst has